In our study, Eotaxin levels were higher in patients with osteopenia and osteoporosis, with no significant differences between the two conditions, suggesting that Eotaxin might be involved in the initial phases of reduction in bone density and could be a promising option for the early detection of BMD loss (Figure 5A). The gene discussed is CCL11; the disease is osteoporosis.